References
- Addington. D., Addington. J. & Maticka-Tyndale. E. (1993). Assessing Depression in Schizophrenia; The Calgary Depression Scale. British Journal of Psychiatry. 163, 39–44.
- Awad. A.G. (1993).Subjective Response toNeuroleptics in Schizophrenia. Schizophrenia Bulletin. 19, 609–617.
- The Clozaril Patient Monitoring Service;.A Summary of its Operation and Scope. Sandoz Pharmaceuti-cals (1993).
- Guy. W. (1976). The Clinical Global Impression Scale.
- ECDEUAssessmentManualforPsychopharmacology, revised DHEW pub no (ADM) 78–388, Rockville, M.D.; National Insti-tute of Mental Health.
- Kane. J.M. (1992). Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia - An Over-view. British Journal of Psychiatry, 160, 41–45.
- Kerwin. R.W. (1994). The New Atypical Antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. British Journal of Psychiatry, 164, 141–148.
- Krupp. P. & Barnes. P. (1992). Clozapine-Associated Agranulocytosis; Risk and Aetiology. British Jour-nal of Psychiatry. 160, 38–40.
- Matheson. L.A., Cook. H.M., McKenna. P. & Bosannquet, N. (1994). Value for money care for patient s w ith schizophrenia.BritishJournal ofMedi-cal Economics, 7, 25–34.
- Meltzer. H.Y. (1992). Dimensions of Outcome with Clozapine. British Journal of Psychiatry, 160, 46–53.
- Overall. J.E. & Gorham. D.R. (1962). The Brief Psy-chiatric Rating Scale. Psychological Reports, 10, 799–812.
- Weiden. P,Rapkin. B, Mott. T, Zygmunt, A., Goldman, D., Horvitz-Lennon, M & Frances. A. (1994). Rating of Medication Influences (ROMI) Scale in Schizophrenia. Schizophrenia Bulletin, 20, 297–309.